MedTrace Logo

The Efficiency of Postoperative Interferon-alpha Treatment in p48 Positive Patients With Hepatocellular Carcinoma

NCT00838968 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2012-08-23

No results posted yet for this study

Summary

The purpose of the study is to determine whether interferon-alpha is effective in the treatment of p48 Positive patients with HCC after curative resection.

Conditions

Interventions

DRUG

interferon-alpha

interferon-alpha is intramuscularly or subcutaneously injected at 3,000,000-5,000,000 U three times a week for 18 months

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Hui-chuan Sun, MD · Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2012-10-31
Completion
2013-01-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00838968 on ClinicalTrials.gov